Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pozen: POZN -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (13)	11/1/2007 2:11:38 PM
From: tuck	Respond to of 19

POZN gets Class II review from FDA on Trexima: >>CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ:POZN - News) announced today that its amended response to the FDA approvable letter for Trexima received on August 1, 2007 has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has also notified POZEN that it considers the submission to be a complete, Class II response (six months) which could result in a new decision date of April 15, 2008.<< snip Cheers, Tuck